Patient-reported Outcomes from Patients Receiving Immunotherapy or Chemo-immunotherapy for Metastatic Non-Small Cell Lung Cancer in Clinical Practice

The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemo-immunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients on these treatments, 20–40% reported moderate symptoms (e.g., rash, muscle ache...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2019-11, Vol.21 (3), p.255-263.e4
Main Authors: McLouth, Laurie E. Steffen, Lycan, Thomas W., Levine, Beverly J., Gabbard, Jennifer, Ruiz, Jimmy, Farris, Michael, Grant, Stefan C., Pajewski, Nicholas M., Weaver, Kathryn E., Petty, W. Jeffrey
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The quality of life and symptom experience for metastatic lung cancer patients treated with immunotherapy or chemo-immunotherapy in routine care has not been described. In our survey of 60 metastatic lung cancer patients on these treatments, 20–40% reported moderate symptoms (e.g., rash, muscle ache). Patient-reported outcomes need to be monitored in clinical practice, especially for patients with worse physical function.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2019.11.015